Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
438 hari yang lalu
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
472 hari yang lalu
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
619 hari yang lalu
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1200 hari yang lalu
Euro Falls Against Majors
The euro weakened against other major currencies in the European session on Monday.
RTTNews
|
5 minit yang lalu
Fastenal Q3 Profit Climbs, But Misses Market View; Stock Down
Shares of Fastenal Co. were losing around 4 percent in the pre-market activity on the Nasdaq, after the company's's third-quarter profit missed market estimates, despite a growth. The provider of industrial and construction supplies recorded higher net sales, but inline with the Street view. Price contributed 240 to 270 basis points to growth, which was lower than expected.
RTTNews
|
19 minit yang lalu
Dollar Surges As Euro, Yen Plunge
The U.S. Dollar rallied emphatically against major currencies during the week ended October 10 amidst political instability in France and Japan that undermined the euro and the yen.
RTTNews
|
1j 43min yang lalu
FTSE 100 Up Marginally; Miners Rise On Higher Metal Prices
The U.K. market is up marginally in late morning trades on Monday, having eased a bit after a fairly decent upmove at the start. Mining stocks are faring well.
RTTNews
|
2j 17min yang lalu
